上海医药：硫酸艾沙康唑原料药上市申请获批准

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Upjohn Kangli (Changzhou) Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the production of Sulfate Isavuconazole active pharmaceutical ingredient, marking a significant advancement in its antifungal drug portfolio [1] Group 1 - The drug Sulfate Isavuconazole is a prodrug of Isavuconazole, which is rapidly converted into its active metabolite in the body by plasma esterases [1] - The registration application for this drug was submitted to the National Medical Products Administration in April 2024 and has been accepted [1]